Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FEMOGEN vs DIVIGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Femogen is a combination of estradiol (an estrogen) and norethindrone acetate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and promoting proliferation of the endometrium. Norethindrone acetate suppresses gonadotropin secretion and inhibits endometrial proliferation, reducing the risk of endometrial hyperplasia associated with estrogen therapy.
Estradiol replacement therapy; binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to proliferation of endometrial and breast epithelium, and modulation of gonadotropin secretion.
Treatment of moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis,Treatment of vulvar and vaginal atrophy,Hormone replacement therapy in hypogonadal women (off-label),Treatment of amenorrhea (off-label)
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis (for women with significant risk, when non-estrogen medications are not appropriate)
1 mg orally once daily for 21 days, followed by 7 days off; for HRT, 1 mg orally once daily continuously.
Transdermal gel: 0.25-1.0 g applied once daily to upper thigh, abdomen, or upper arm. Each gram contains 1 mg estradiol.
Terminal half-life: 13.2 ± 2.3 hours; clinically, steady-state reached after 3-5 days.
Terminal elimination half-life of estradiol is 13-15 hours; clinical context: due to enterohepatic recirculation, serum levels may fluctuate; transdermal delivery avoids first-pass hepatic metabolism, resulting in more stable levels
Estradiol is metabolized primarily in the liver via conversion to estrone and estriol, and undergoes hydroxylation and conjugation (glucuronidation and sulfation). Norethindrone acetate is hydrolyzed to norethindrone, which is metabolized via reduction, hydroxylation, and conjugation (primarily glucuronidation). Enzymes involved include CYP3A4 for norethindrone.
No adjustment required; estradiol is not significantly renally cleared.
No specific dose adjustment recommended based on GFR; estradiol is not significantly renally cleared.
Contraindicated in severe hepatic disease; for mild-moderate impairment (Child-Pugh A or B), reduce dose by 50% and monitor liver function.
Estrogens and progestins should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) receiving 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate. The Women's Health Initiative Memory Study (WHIMS) reported an increased risk of probable dementia in women ≥65 years of age taking estrogen plus progestin.
FEMOGEN is contraindicated in pregnancy. First trimester: Estrogens and progestins have been associated with congenital anomalies, including cardiovascular and limb defects, and an increased risk of vaginal adenosis and clear-cell adenocarcinoma in female offspring. Second and third trimesters: Use may cause fetal harm, including urogenital abnormalities and feminization of male fetuses.
Divigel (estradiol) is contraindicated in pregnancy. Estrogens are associated with an increased risk of congenital anomalies, including cardiovascular and urogenital defects, when used during the first trimester. In the second and third trimesters, exposure may cause feminization of male fetuses, functional genital tract abnormalities, and potential long-term reproductive effects. Use is not recommended at any stage.
FEMOGEN (estradiol/norethindrone acetate) is a continuous combined HRT; first-line for moderate-to-severe vasomotor symptoms in postmenopausal women with an intact uterus. Avoid in women with known or suspected pregnancy, undiagnosed abnormal genital bleeding, known/suspected breast cancer, or active thromboembolic disorders. Baseline and periodic mammography and bone density assessment are recommended. Start at lowest effective dose (0.5 mg/0.1 mg or 1 mg/0.5 mg). Not for women within 10 years of menopause onset; consider transdermal route to reduce thromboembolism risk.
Divigel (estradiol gel) is a transdermal estrogen therapy for moderate-to-severe vasomotor symptoms of menopause. Apply to clean, dry, non-irritated skin on upper thigh or calf, rotating sites daily. Do not apply to breasts or genital area. Avoid sun exposure or heating pads over application site. Monitor for endometrial hyperplasia; add progestin if uterus intact.
No interactions on record
No interactions on record
Common clinical questions about FEMOGEN vs DIVIGEL, answered by our medical review team.
FEMOGEN is a Estrogen that works by Femogen is a combination of estradiol (an estrogen) and norethindrone acetate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and promoting proliferation of the endometrium. Norethindrone acetate suppresses gonadotropin secretion and inhibits endometrial proliferation, reducing the risk of endometrial hyperplasia associated with estrogen therapy.. DIVIGEL is a Estrogen that works by Estradiol replacement therapy; binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to proliferation of endometrial and breast epithelium, and modulation of gonadotropin secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FEMOGEN and DIVIGEL depend on the specific clinical indication. These are both Estrogen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FEMOGEN is: 1 mg orally once daily for 21 days, followed by 7 days off; for HRT, 1 mg orally once daily continuously.. The standard adult dose of DIVIGEL is: Transdermal gel: 0.25-1.0 g applied once daily to upper thigh, abdomen, or upper arm. Each gram contains 1 mg estradiol.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FEMOGEN and DIVIGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FEMOGEN is classified as Category C. FEMOGEN is contraindicated in pregnancy. First trimester: Estrogens and progestins have been associated with congenital anomalies, including cardiovascular and limb defects, and an. DIVIGEL is classified as Category C. Divigel (estradiol) is contraindicated in pregnancy. Estrogens are associated with an increased risk of congenital anomalies, including cardiovascular and urogenital defects, when . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Primarily hepatic metabolism via CYP3A4; also undergoes conjugation (glucuronidation) and sulfation; enterohepatic recirculation.
Renal: 60-70% as glucuronide conjugates; Biliary/Fecal: 30-40% as metabolites; <1% unchanged.
Urine (approximately 90-95% as glucuronide and sulfate conjugates, with less than 5% as unchanged drug); feces (approximately 5-10% via biliary excretion)
97-99% bound to albumin and sex hormone-binding globulin (SHBG).
98-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin
3.4 ± 0.8 L/kg; distributes into adipose tissue and reproductive organs.
Vd approximately 1-2 L/kg, indicating extensive distribution into tissues; clinical meaning: reflects wide distribution to target organs such as breast, uterus, and adipose tissue
Oral: 5-10% (extensive first-pass metabolism).
Transdermal gel: approximately 10-20% of the applied dose (due to incomplete absorption and retention in the skin depot); avoids first-pass hepatic metabolism, thus effective at lower doses compared to oral
Contraindicated in severe hepatic dysfunction (Child-Pugh class C). In mild to moderate (Child-Pugh A/B), use with caution and monitor.
Not FDA-approved for use in children; no established dosing.
Not FDA-approved for use in children; efficacy and safety not established.
Use lowest effective dose for shortest duration; increased risk of thromboembolism and malignancy; monitor closely.
Use lowest effective dose; consider increased risk of thromboembolic events, cardiovascular disease, and dementia in women >65 years.
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risk of venous thromboembolism, stroke, and possibly dementia. Estrogen plus progestin has been associated with increased risk of breast cancer, stroke, VTE, and dementia.
Cardiovascular disorders (e.g., coronary heart disease, stroke, VTE), malignant neoplasms (endometrial cancer, breast cancer), gallbladder disease, hypercalcemia, fluid retention, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, hepatic hemangiomas, exacerbation of endometriosis, severe hypocalcemia in hypoparathyroidism, and thyroid hormone effects.
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or history of venous thromboembolism; active or history of arterial thromboembolism; known anaphylactic reaction or angioedema to estradiol; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency; known thrombophilic disorders; pregnancy; hypersensitivity to any ingredient.
Grapefruit and grapefruit juice may increase estradiol levels; avoid concurrent consumption. High-fat meals may increase absorption; maintain consistent timing relative to meals. No known interaction with alcohol, but limit intake to reduce breast cancer risk.
No significant food interactions. Grapefruit juice may increase estradiol exposure; avoid excessive intake.
FEMOGEN is not recommended during breastfeeding. Small amounts of estrogens and progestins are excreted in breast milk; M/P ratio is not established. Potential adverse effects include reduced milk production and altered breast milk composition. Use only if clearly needed and consider alternative contraception.
Estradiol is excreted into human breast milk in small amounts. The M/P ratio is not specifically reported for Divigel; however, estradiol levels in milk are low. Effects on the nursing infant are not well studied, but potential for adverse effects exists. Divigel is not recommended during breastfeeding.
No dosing adjustments are applicable as FEMOGEN is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic metabolism) are not relevant due to absolute contraindication. Alternative therapy should be initiated.
Divigel has no approved use in pregnancy; dose adjustments are not applicable. Use is contraindicated.
Take FEMOGEN at the same time each day, with or without food.,Do not take if you are pregnant, breastfeeding, or planning to become pregnant.,Report any unusual vaginal bleeding, breast lumps, chest pain, shortness of breath, or leg swelling immediately.,Smoking increases risk of serious cardiovascular events; stop smoking if possible.,Regular mammograms and pelvic exams are essential while on this medication.,Possible side effects include bloating, breast tenderness, mood changes, and headache.,Store at room temperature away from moisture and heat.
Apply gel at the same time each day to clean, dry skin on upper thigh or calf. Rotate application sites daily.,Do not apply to breasts, face, or genital area. Avoid contact with others until gel dries (about 5 minutes).,Wash hands thoroughly after application. Avoid water, sunscreen, or lotion on the application site for 2-3 hours.,Report unusual vaginal bleeding, breast lumps, leg pain, or jaundice immediately.,Do not smoke or use nicotine products while on estrogen therapy.